

iD-AD

An accredited section 3 self-learning program on **Alzheimer's disease awareness and management**



This e-learning activity, developed by neurologists and neuroradiologists, is designed for physicians to assess their knowledge of Alzheimer's disease awareness and management through case-based learning.

Estimated completion time: 2 hours

Program available until September 2025

SCIENTIFIC PLANNING COMMITTEE



Santanu Chakraborty
MBBS
Neuroradiologist
Ottawa, ON




Rafael Glikstein
MD
Neuroradiologist
Ottawa, ON



Alex Henri-Bhargava
MD
Neurologist
Victoria, BC



Andrew Kirk
MD
Neurologist
Saskatoon, SK



Sara Mitchell
MD
Neurologist
Toronto, ON

LEARNING OBJECTIVES

After completion of this course, participants will be able to:

1. Use clinical tools to assess signs and symptoms for diagnosis of Alzheimer's disease (AD).
2. Assess the role of different biomarkers in the detection and diagnosis of AD.
3. Interpret neuroimaging findings to detect structural abnormalities associated with AD.
4. Explain use of non-pharmacological and symptomatic interventions for AD.
5. Discuss the status of emerging disease-modifying therapies and identify potential associated adverse events such as amyloid-related imaging abnormalities – edema/effusion (ARIA-E) and amyloid-related imaging abnormalities – hemorrhagic (ARIA-H).
6. Explain how and when to monitor disease progression and determine the next steps in clinical management.

Visit [id-alzheimers.ca](https://www.id-alzheimers.ca) to access the program

This event is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Neurological Sciences Federation for 3.0 credits per hour, up to a maximum of 6.0 credits total. This program was co-developed by the Canadian Neurological Sciences Federation and Eli Lilly Canada, and was planned to achieve scientific integrity, objectivity and balance.